Lixia Gao

About

Gao Lixia, female, Han nationality, professor of Xinjiang Second Medical College, master supervisor She is good at the diagnosis and treatment of hematology-oncology diseases, and has unique insights into the occurrence and development of many hematological diseases. He has accumulated rich experience in the diagnosis and treatment of various malignant lymphomas, multiple myeloma, acute and chronic leukemia, various anemias, systemic chemotherapy and difficult diseases, and has won many academic honors. At present, he is responsible for the MDT studio of the Myeloma Multidisciplinary Consultation Center for Lymphadenopathy, the regular follow-up of new lymphadenopathy and diagnosis and treatment cases, and the establishment of chronic disease management and follow-up of patients with malignant tumors. Special research on hematological tumor thrombosis and prevention and treatment, and held "thrombotic disease training courses" for many times. Every year, he participates in 248 discussions of difficult cases in specialized ward rounds, and participates in more than 30 consultations between tertiary hospitals and remote consultations. In 2018, he was awarded the title of "Tianshan Youth Grassroots Young Scientific and Technological Talent", and in 2023, he was awarded the title of the first Famous Doctor of the Oil City of Karamay City. In 2024, he will be awarded the honor of "Discipline Leader". Director of the Teaching and Research Department of Xinjiang Second Medical College, he has won the Outstanding Teacher, Outstanding Resident Training Tutor and Teaching Teacher of Xinjiang Second Medical College for many times, and won the second prize of the Teaching Innovation Competition of Xinjiang Second Medical College in 2023.

Employment

• Department of Hematology Oncology of Karamay Central Hospital, number 120, Anding Road, Karamay region, Karamay city, the Xinjiang Uygur Autonomous Region of China, 834000, P.R.China Deputy Head of Department

Education

• Karamay Central Hospital Master
  2004 - 2007

Projects & Funding

Projects & funding information is unavailable.

Publications (6)

• Metformin Inhibits Multiple Myeloma Serum-induced Endothelial Cell Thrombosis by Down-Regulating miR-532
  Annals of Vascular Surgery 2022 DOI: 10.1016/j.avsg.2022.04.035
  +Save
• Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy
  Frontiers in Immunology 2022 DOI: 10.3389/fimmu.2022.982346
  +Save
• Effects of hsa-miR-28-5p on Adriamycin Sensitivity in Diffuse Large B-Cell Lymphoma
  Evidence-Based Complementary and Alternative Medicine 2022 DOI: 10.1155/2022/4290994
  +Save
• NEDD4L inhibits cell viability, cell cycle progression, and glutamine metabolism in esophageal squamous cell carcinoma via ubiquitination of c-Myc
  Acta Biochimica et Biophysica Sinica 2022 DOI: 10.3724/abbs.2022048
  +Save
• A multiple genomic data fused SF2 prediction model, signature identification, and gene regulatory network inference for personalized radiotherapy
  Technology in Cancer Research & Treatment 2020 DOI: 10.1177/1533033820909112
  +Save
• Changes in Biomarkers of Coagulation, Fibrinolytic, and Endothelial Functions for Evaluating the Predisposition to Venous Thromboembolism in Patients With Hereditary Thrombophilia
  Clinical and Applied Thrombosis/Hemostasis 2020 DOI: 10.1177/1076029620944471
  +Save